Copyright
©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Dec 10, 2014; 5(5): 1028-1035
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.1028
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.1028
Table 1 Selected grade 3/4 adverse events (%) with FOLFIRI/ziv-aflibercept in VELOUR study
| Adverse event | Grade 3 % | Grade 4 % |
| Fatigue | 11.9 | 0.7 |
| Asthenia | 4.9 | 0.2 |
| Proteinuria | 7.5 | 0.3 |
| Urinary tract infections | 0.8 | 0.0 |
| Neutropenia | 23.1 | 13.6 |
- Citation: Saif MW, Relias V, Syrigos K, Gunturu KS. Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer. World J Clin Oncol 2014; 5(5): 1028-1035
- URL: https://www.wjgnet.com/2218-4333/full/v5/i5/1028.htm
- DOI: https://dx.doi.org/10.5306/wjco.v5.i5.1028